Welcome to LookChem.com Sign In|Join Free

CAS

  • or

183677-69-2

Post Buying Request

183677-69-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

183677-69-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 183677-69-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,3,6,7 and 7 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 183677-69:
(8*1)+(7*8)+(6*3)+(5*6)+(4*7)+(3*7)+(2*6)+(1*9)=182
182 % 10 = 2
So 183677-69-2 is a valid CAS Registry Number.

183677-69-2Relevant articles and documents

N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay

Furuya, Takeru,Shapiro, Adam B.,Comita-Prevoir, Janelle,Kuenstner, Eric J.,Zhang, Jing,Ribe, Seth D.,Chen, April,Hines, Daniel,Moussa, Samir H.,Carter, Nicole M.,Sylvester, Mark A.,Romero, Jan A.C.,Vega, Camilo V.,Sacco, Michael D.,Chen, Yu,O'Donnell, John P.,Durand-Reville, Thomas F.,Miller, Alita A.,Tommasi, Ruben A.

, (2020)

UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase (LpxC), the zinc metalloenzyme catalyzing the first committed step of lipid A biosynthesis in Gram-negative bacteria, has been a target for antibacterial drug discovery for many years. All inhibitor chemotypes reaching an advanced preclinical stage and clinical phase 1 have contained terminal hydroxamic acid, and none have been successfully advanced due, in part, to safety concerns, including hemodynamic effects. We hypothesized that the safety of LpxC inhibitors could be improved by replacing the terminal hydroxamic acid with a different zinc-binding group. After choosing an N-hydroxyformamide zinc-binding group, we investigated the structure-activity relationship of each part of the inhibitor scaffold with respect to Pseudomonas aeruginosa and Escherichia coli LpxC binding affinity, in vitro antibacterial potency and pharmacological properties. We identified a novel, potency-enhancing hydrophobic binding interaction for an LpxC inhibitor. We demonstrated in vivo efficacy of one compound in a neutropenic mouse E. coli infection model. Another compound was tested in a rat hemodynamic assay and was found to have a hypotensive effect. This result demonstrated that replacing the terminal hydroxamic acid with a different zinc-binding group was insufficient to avoid this previously recognized safety issue with LpxC inhibitors.

Effect of extended conjugation with a phenylethynyl group on the fluorescence properties of water-soluble arylboronic acids

Zheng, Shi-Long,Lin, Na,Reid, Suazette,Wang, Binghe

, p. 5427 - 5436 (2008/01/07)

Boronic acids that change fluorescence properties upon sugar binding are very important reporter units for the development of small molecule lectin mimics (boronolectins). Aimed at developing long wavelength fluorescent boronic acid reporter compounds, we

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 183677-69-2